ALX ONCOLOGY HOLDINGS INC
ALX Oncology is a clinical-stage biopharmaceutical company advancing therapies that boost the immune system to treat cancer. Their lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. They focus on developing novel approaches to optimize current and future standards of cancer care.
Registre Officiel
Dernière vérification: 1/2/2026
Analyse Qualité IA
Détails du Score de Confiance
Liens Rapides
Points forts du site
🌟 Entreprises similaires de confiance
Kalaris Therapeutics, Inc.
Kalaris is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases. They focus on innovative retinal treatments, including TH103, a potential best-in-class anti-VEGF agent for neovascular AMD. Kalaris aims to ease patient burden and improve outcomes in retinal disease management.
PUMA BIOTECHNOLOGY, INC.
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer. They focus on in-licensing innovative drug candidates that have undergone clinical testing. Puma Biotechnology aims to improve cancer treatment through innovative drug development.
Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals is a patient-centric biopharmaceutical company focused on developing treatments for episodic cardiovascular conditions. Their FDA-approved product, CARDAMYST™, is a self-administered treatment for acute symptomatic episodes of PSVT. They are also investigating etripamil for AFib-RVR. Milestone is dedicated to improving the lives of patients by providing solutions that can be self-administered when needed.